ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ELDN Eledon Pharmaceuticals Inc

1.97
-0.19 (-8.80%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 100,805
Bid Price 1.90
Ask Price 2.08
News -
Day High 2.20

Low
1.07

52 Week Range

High
2.95

Day Low 1.96
Company Name Stock Ticker Symbol Market Type
Eledon Pharmaceuticals Inc ELDN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.19 -8.80% 1.97 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.18 1.96 2.20 1.97 2.16
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
434 100,805 $ 2.08 $ 210,061 - 1.07 - 2.95
Last Trade Time Type Quantity Stock Price Currency
19:13:16 50 $ 2.06 USD

Eledon Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
47.67M 24.20M - 0 -40.33M -1.67 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Eledon Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ELDN Message Board. Create One! See More Posts on ELDN Message Board See More Message Board Posts

Historical ELDN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.582.201.551.98255,7070.3924.68%
1 Month2.122.201.521.89123,510-0.15-7.08%
3 Months1.772.231.51991.8788,3740.2011.30%
6 Months1.422.231.071.6889,8820.5538.73%
1 Year2.612.951.071.85113,697-0.64-24.52%
3 Years10.6411.691.073.2272,054-8.67-81.48%
5 Years15.8022.911.074.2071,466-13.83-87.53%

Eledon Pharmaceuticals Description

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Your Recent History

Delayed Upgrade Clock